Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)

What is the purpose of this trial?

The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS).

Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.

Participation Guidelines

Ages: 30 - 80 years

Gender: Both

Yale University School of Medicine

Start Date: 06/11/2015

End Date: 01/23/2020

Last Updated: 02/22/2018

Study HIC#: 1501015246

Get Involved

For more information about this study, contact:
Marta Boeke
+1 203-785-2863

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image